IN BRIEF: ValiRx shares up as subsidiary inks contract with US firm

ValiRx PLC - life sciences company focused on early-stage cancer therapeutics and women's health ...

Alliance News 17 June, 2024 | 1:29PM
Email Form Facebook Twitter LinkedIn RSS

ValiRx PLC - life sciences company focused on early-stage cancer therapeutics and women's health - Notes that its subsidiary Inaphaea BioLabs Limited wins a "revenue-bearing" contract for the provision of patient derived cell based services with a US-based biotech company. "The contract is a multi-stage project and encompasses analysis and provision of RNA data, acquired as part of the scientific package from Imagen Therapeutics, in addition to bespoke cell-based screening in the laboratory," ValiRx explains.

Andrew Carnegie, head of Strategic Commercial Development at Inaphaea, says: "It's encouraging to have secured this contract in the exciting area of immuno-oncology, which will be a great opportunity to showcase our skills and leveraging our patient derived cells in this area. The US biotech market is a strong location to seek clients for Inaphaea and this contract is a positive step towards establishing our brand in further geographical regions."

Current stock price: 2.68 pence per share, up 3.0% on Monday afternoon in London

12-month change: down 65%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
ValiRx PLC 2.66 GBX -1.48 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures